Oric Pharmaceuticals (NASDAQ:ORIC) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Oric Pharmaceuticals (NASDAQ:ORIC) from a strong sell rating to a sell rating in a report released on Saturday morning.

ORIC has been the topic of several other research reports. Cantor Fitzgerald restated an “overweight” rating on shares of Oric Pharmaceuticals in a report on Friday, May 22nd. HC Wainwright reiterated a “buy” rating and set a $25.00 price objective on shares of Oric Pharmaceuticals in a report on Monday, June 8th. Citigroup decreased their target price on shares of Oric Pharmaceuticals from $17.00 to $16.00 and set a “buy” rating for the company in a research report on Tuesday, May 5th. The Goldman Sachs Group upgraded shares of Oric Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $15.00 target price on the stock in a report on Friday, May 15th. Finally, Stifel Nicolaus initiated coverage on shares of Oric Pharmaceuticals in a research report on Friday, June 12th. They issued a “buy” rating and a $14.00 price target on the stock. Thirteen analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Oric Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $19.27.

Oric Pharmaceuticals Stock Down 0.7%

NASDAQ ORIC opened at $12.02 on Friday. Oric Pharmaceuticals has a 52 week low of $7.23 and a 52 week high of $14.93. The business has a 50 day moving average price of $9.47 and a 200-day moving average price of $10.34. The company has a market cap of $1.24 billion, a price-to-earnings ratio of -8.35 and a beta of 1.02.

Oric Pharmaceuticals (NASDAQ:ORIC) last issued its earnings results on Monday, May 4th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.03). On average, equities research analysts anticipate that Oric Pharmaceuticals will post -1.45 earnings per share for the current year.

Institutional Investors Weigh In On Oric Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Federation des caisses Desjardins du Quebec lifted its stake in Oric Pharmaceuticals by 100.0% during the 4th quarter. Federation des caisses Desjardins du Quebec now owns 4,000 shares of the company’s stock valued at $33,000 after acquiring an additional 2,000 shares in the last quarter. Caitong International Asset Management Co. Ltd grew its stake in shares of Oric Pharmaceuticals by 184.4% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 4,528 shares of the company’s stock worth $37,000 after acquiring an additional 2,936 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Oric Pharmaceuticals by 26.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,732 shares of the company’s stock worth $39,000 after acquiring an additional 977 shares in the last quarter. Russell Investments Group Ltd. purchased a new stake in shares of Oric Pharmaceuticals in the third quarter valued at about $60,000. Finally, CANADA LIFE ASSURANCE Co purchased a new stake in shares of Oric Pharmaceuticals in the third quarter valued at about $65,000. 95.05% of the stock is owned by hedge funds and other institutional investors.

About Oric Pharmaceuticals

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.